Navigation Links
Coloplast Delivers On Ambitious Targets With Solid Interim Report
Date:8/13/2014

MINNEAPOLIS, Aug. 13, 2014 /PRNewswire/ -- Danish medical device company Coloplast delivered revenue of USD* 1,654 million (DKK 9,214 million) and 9% organic growth in the first nine months of the 2013/14 financial year. Q3 organic growth was 8%.

EBIT before special items was up by 13% to USD 547 million (DKK 3,047 million). The EBIT margin before special items was 33% against 31% in 9M 2012/13.

Delivering on ambitious targets
"I'm pleased with the solid financial results we are announcing today. We are continuing our string of healthy growth in all business areas and in all regions, and our consolidated profit is matching the high expectations we have for our company," said Coloplast CEO Lars Rasmussen.

Global sales growth by business area was as follows: Ostomy Care 8%, Continence Care 11%, Urology Care 10% and Wound & Skin Care 10%. Coloplast grew its European business by 6%, Other Developed Markets by 10% and Emerging Markets by 24%.

Consumer centered strategy
Senior Vice President, Chronic Care US, Ed Veome says: "The US is an important market for Coloplast and we have invested to grow our business as we see great potential. It is very encouraging that we have seen strong sales performance in our continence and ostomy care product lines."

"We're pursuing a strategy that puts the consumer in the center. The majority of our users in the US have overcome critical conditions that led them to our products, and we want to help them return to their normal lives. We can only do that by listening and responding to their needs."

Coloplast employs more than 500 people in the US and has it US headquarter in Minneapolis, Minnesota. Globally Coloplast employs more than 9.000 with its products being sold in more than 100 countries around the world. Coloplast is listed on the Copenhagen Stock Exchange, part of the NASDAQ OMX Group and has a market cap of around USD 18 billion (DKK 100 billion).

Financial guidance for 2013/14 unchanged
Following the Q3 interim report, Coloplast continues to expect full-year organic revenue growth of about 9% and of about 7% in DKK. The company continues to expect the EBIT margin before special items to be 33-34% at constant exchange rates and about 33% in DKK.

For further information, click here to read the Q3 Interim Report.

*At exchange rate USD/DKK 5,57

www.coloplast.com Financial highlights and key ratios Financial highlights
and key ratios
DKKm9M
2013/149M
2012/13ChangeFY 2012/13Revenue

9,214

8,665

6%

11,635EBIT

2,047

2,699

(24%)

3,672EBIT margin

22%

31%

(9) p.p.

32%Special items

1,000

-

-

-EBIT before special items

3,047

2,699

13%

3,672EBIT margin before special items

33 %

31%

2 p.p.

32%Sales performance by
business area 9M
2013/14
DKKm9M
2012/13
DKKmOrganic growthReported growthOstomy Care

3,764

3,613

8%

4%Continence Care

3,288

3,029

11%

9%Urology Care

898

844

10%

6%Wound & Skin Care

1,264

1,179

10%

7%Revenue9,214

8,665

9%

6%Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare. Our business includes ostomy care, urology and continence care and wound and skin care. We operate globally and employ more than 9,000 people.


'/>"/>
SOURCE Coloplast
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Coloplast Wins Patent Infringement Verdict Against Generic Medical Devices, Inc.
2. First Paralyzed Formula Race Car Drivers "Road to Indy" Sponsored By Coloplast
3. Coloplast Launches the Innovative Altis Single Incision Sling System
4. Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
5. Direct Relief Delivers Hurricane Packs As FEMA Urges Preparedness
6. Bayer Partnership Delivers Industry-First Dose Management Offering
7. Largest Public Hospital in Sydney Delivers First Treatment in Australia Using Advanced TrueBeam Radiotherapy and Radiosurgery Device
8. MIOT Hospital Delivers First TrueBeam STx Radiotherapy Treatment in Chennai
9. New Fluke intrinsically safe digital multimeter delivers extreme ruggedness for use in potentially explosive environments
10. Del Mar CEO Delivers Keynote Address at International Drug Discovery Science and Technology Conference
11. Cloudnine Group of Hospitals Delivers 12 Babies by Mid-day on 12/12/12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016  SciClone Pharmaceuticals, Inc. ... it has entered into a settlement agreement with ... fully resolving the SEC,s investigation into possible violations ... the terms of the settlement agreement, SciClone has ... including disgorgement, pre-judgment interest and a penalty.  This ...
(Date:2/4/2016)... Feb. 4, 2016 Global Immunology Market ... to drive long-term market growth Summary ... of chronic disorders that affect 5–7% of western ... of their symptoms and key patient demographics, they ... immune pathways and an inappropriate immune response. Generally, ...
(Date:2/4/2016)... DIEGO, Feb. 4, 2016  Aethlon Medical, Inc. ... affinity biofiltration devices to treat life-threatening diseases, today ... 2016 ended December 31, 2015. ... objectives set forth in our last quarterly call, ... reinforce our long-term objective to establish the Aethlon ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Successful recruitment ... new clinical and scientific initiatives have all marked the last 12 months at ... and CEO of the nation’s oldest cancer center, Candace S. Johnson, PhD, outlined ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... life? The answer may be at the tips of your toes. Foot massage, whether ... as well as pure comfort and relaxation. The American Board of Multiple Specialties ...
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps ... in Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio is centrally ... one hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure ... search for and donate to Give To Cure’s campaign that is crowdfunding clinical trials ... users make and share payments through a smart device. In 2015 alone, Venmo processed ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Dr. Justin ... announce their 2nd Annual No Cost Dental Day to individuals in need. The event ... purpose of this No Cost Dental Day is to provide dental care to community ...
Breaking Medicine News(10 mins):